Reassurance on DOACs in AF patients with bioprosthetic valves

Rivaroxaban is non-inferior to warfarin in terms of efficacy and safety in the management of patients with atrial fibrillation and a bioprosthetic mitral valve, a study shows. The Rivaroxaban for Valvular Heart Disease and Atrial Fibrillation (RIVER) trial, published in the NEJM, randomised 1,005 patients to either rivaroxaban (20 mg once daily) or warfarin (adjusted ...

Already a member?

Login to keep reading.

© 2021 the limbic